Small cell lung cancer (SCLC) is traditionally classified into limited-stage SCLC (LS-SCLC) and extensive-stage SCLC according to whether disease is confined to one hemithorax or not. Approximately 10% of patients present with stage II and 4% with stage I SCLC under the American Joint Committee on Cancer staging system. Surgery remains a leading approach for patients with node-negative SCLC, among whom long-term survival was in the 50% range in retrospective series, exceeding expected results for a broader population with LS-SCLC.
https://ift.tt/2UJT0J5
Medicine by Alexandros G. Sfakianakis,Anapafseos 5 Agios Nikolaos 72100 Crete Greece,00302841026182,00306932607174,alsfakia@gmail.com,
Ετικέτες
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
-
Publication date: September 2017 Source: European Journal of Surgical Oncology (EJSO), Volume 43, Issue 9 http://ift.tt/2gezJ2D
-
Publication date: January–February 2018 Source: Materials Today, Volume 21, Issue 1 Author(s): David Bradley http://ift.tt/2BP...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου